title: Effect of xanthohumol and 8-prenylnaringenin on MCF-7 breast cancer cells oxidative stress and mitochondrial complexes expression.
abstract: Xanthohumol (XN) and 8-prenylnaringenin (8PN) are hop (Humulus lupulus L.) polyphenols studied for their chemopreventive effects on certain cancer types. The breast cancer line MCF-7 was treated with doses ranging from 0.001 to 20 µM of XN or 8PN in order to assess the effects on cell viability and oxidative stress. Hoechst 33342 was used to measure cell viability and reactive oxygen species (ROS) production was determined by 2',7'-dichlorofluorescein diacetate. Catalase, superoxide dismutase, and glutathione reductase enzymatic activities were determined and protein expression of sirtuin1, sirtuin3, and oxidative phosphorylation system (OXPHOS) were done by Western blot. Treatments XN 0.01, 8PN 0.01, and 8PN 1 µM led to a decrease in ROS production along with an increase of OXPHOS and sirtuin expression; in contrast, XN 5 µM gave rise to an increase of ROS production accompanied by a decrease in OXPHOS and sirtuin expression. These results suggest that XN in low dose (0.01 µM) and 8PN at all assayed doses (0.001-20 µM) presumably improve mitochondrial function, whereas a high dose of XN (5 µM) worsens the functionality of this organelle.
authors.affiliation: Grupo Multidisciplinar de Oncología Translacional, Institut Universitari d'Investigació en Ciències de la Salut (IUNICS), Palma de Mallorca, Illes Balears, Spain; Ciber Fisiopatología Obesidad y Nutrición (CB06/03) Instituto Salud Carlos III, Madrid, Spain.
authors.forename: M Mar
authors.initials: MM
authors.lastname: Blanquer-Rosselló
authors.forename: Jordi
authors.initials: J
authors.lastname: Oliver
authors.forename: Adamo
authors.initials: A
authors.lastname: Valle
authors.forename: Pilar
authors.initials: P
authors.lastname: Roca
mesh_terms: D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D002374:Catalase / Q000378:metabolism; D002470:Cell Survival / Q000187:drug effects*; D042967:Electron Transport Complex I / Q000378:metabolism; D005260:Female; D044950:Flavanones / Q000008:administration & dosage*; D005419:Flavonoids / Q000008:administration & dosage*; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D005980:Glutathione Reductase / Q000378:metabolism; D006801:Humans; D061986:MCF-7 Cells; D008928:Mitochondria; D018384:Oxidative Stress / Q000187:drug effects*; D011427:Propiophenones / Q000008:administration & dosage*; D017382:Reactive Oxygen Species / Q000378:metabolism; D013482:Superoxide Dismutase / Q000378:metabolism
chemical_list: C119737:8-prenylnaringenin; D044950:Flavanones; D005419:Flavonoids; D011427:Propiophenones; D017382:Reactive Oxygen Species; D002374:Catalase; D013482:Superoxide Dismutase; D005980:Glutathione Reductase; D042967:Electron Transport Complex I; C104536:xanthohumol
keywords: 8-PRENYLNARINGENIN; BREAST CANCER; MCF-7; MITOCHONDRIA; OXIDATIVE PHOSPHORYLATION SYSTEM; OXIDATIVE STRESS; SIRTUINS; XANTHOHUMOL